Kiadis Buying CytoSen Will Combine Natural Killer And T-Cell Immunotherapies
An all-stock transaction will see Europe’s Kiadis and US’s CytoSen bring together complementary approaches to improving stem cell transplants and cancer immunotherapy.
You may also be interested in...
Arthur Lahr, CEO of the Dutch biotech, said the offer is testimony to the uniqueness of the firm's natural killer (NK) cell platform "and the rapid success of Kiadis’s transformation."
Sanofi is paying €17.5m upfront to combine a preclinical NK cell product with its anti-CD38 antibody Sarclisa and develop a multiple myeloma drug that potentially may prove more effective than J&J's Darzalex, Kiadis's CEO tells Scrip.
Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.